The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Rong Zhang - One of the best experts on this subject based on the ideXlab platform.
-
Lycorine inhibits cell proliferation and migration by inhibiting rock1 cofilin induced actin dynamics in hepg2 hepatoblastoma cells
Oncology Reports, 2018Co-Authors: Wuyi Liu, Qian Zhang, Qin Tang, Jingbin Huang, Yali Liu, Qing Wang, Rong ZhangAbstract:Lycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit anti‑cancer effects in various types of cancer cells. However, the molecular mechanisms through which Lycorine exhibits anti‑hepatoblastoma activity are unclear. In the present study, the inhibitory effects of Lycorine on the proliferation and migration of HepG2 hepatoblastoma cells were investigated. Lycorine inhibited the proliferation of HepG2 cells in a dose‑dependent manner by inducing cell cycle arrest at the G2/M phase, via downregulation of cyclin A, cyclin B1 and cyclin dependent kinase 1. Additionally, wound healing and Transwell assays revealed that treatment with Lycorine resulted in a decrease in the migratory ability of HepG2 cells. Also, treatment with Lycorine decreased the expression levels of matrix metalloproteinase (MMP)‑9 and MMP‑2. Furthermore, Lycorine induced the cleavage/activation of Rho associated coiled‑coil containing protein kinase 1 (ROCK1) and the downregulation of cofilin, accompanied by an increase in polymerized filamentous actin and a loss of depolymerized globular actin. Furthermore, pre‑incubation of cells with Y‑27632, a specific ROCK1 inhibitor, markedly attenuated Lycorine‑induced anti‑proliferative and anti‑migration effects. Taken together, the results demonstrated that Lycorine inhibited the proliferation and migration of HepG2 cells by suppressing ROCK1/cofilin‑induced actin dynamics, which suggests that Lycorine has the potential to be developed into a novel drug for hepatoblastoma treatment.
-
Lycorine inhibits cell proliferation and migration by inhibiting ROCK1/cofilin‑induced actin dynamics in HepG2 hepatoblastoma cells.
Oncology reports, 2018Co-Authors: Wuyi Liu, Qian Zhang, Qin Tang, Jingbin Huang, Yali Liu, Wang Qing, Rong ZhangAbstract:Lycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit anti‑cancer effects in various types of cancer cells. However, the molecular mechanisms through which Lycorine exhibits anti‑hepatoblastoma activity are unclear. In the present study, the inhibitory effects of Lycorine on the proliferation and migration of HepG2 hepatoblastoma cells were investigated. Lycorine inhibited the proliferation of HepG2 cells in a dose‑dependent manner by inducing cell cycle arrest at the G2/M phase, via downregulation of cyclin A, cyclin B1 and cyclin dependent kinase 1. Additionally, wound healing and Transwell assays revealed that treatment with Lycorine resulted in a decrease in the migratory ability of HepG2 cells. Also, treatment with Lycorine decreased the expression levels of matrix metalloproteinase (MMP)‑9 and MMP‑2. Furthermore, Lycorine induced the cleavage/activation of Rho associated coiled‑coil containing protein kinase 1 (ROCK1) and the downregulation of cofilin, accompanied by an increase in polymerized filamentous actin and a loss of depolymerized globular actin. Furthermore, pre‑incubation of cells with Y‑27632, a specific ROCK1 inhibitor, markedly attenuated Lycorine‑induced anti‑proliferative and anti‑migration effects. Taken together, the results demonstrated that Lycorine inhibited the proliferation and migration of HepG2 cells by suppressing ROCK1/cofilin‑induced actin dynamics, which suggests that Lycorine has the potential to be developed into a novel drug for hepatoblastoma treatment.
Wuyi Liu - One of the best experts on this subject based on the ideXlab platform.
-
Lycorine Induces Mitochondria-Dependent Apoptosis in Hepatoblastoma HepG2 Cells Through ROCK1 Activation
Frontiers in pharmacology, 2019Co-Authors: Wuyi Liu, Qian Zhang, Qin Tang, Jingbin Huang, Yali Liu, Fangfang Sheng, Min Zhou, Wenjing LaiAbstract:Lycorine, a naturally occurring compound extracted from the Amaryllidaceae plant family, has been reported to exhibit antitumour activity in various cancer cell types. In the present study, we investigated the molecular mechanisms underlying Lycorine-induced apoptosis in hepatoblastoma HepG2 cells. We found that Lycorine induced mitochondria-dependent apoptosis in HepG2 cells accompanied by mitochondrial permeability transition pore (mPTP) opening, mitochondrial membrane potential (MMP) loss, adenosine triphosphate (ATP) depletion, Ca2+ and cytochrome c (Cyto C) release, as well as caspase activation. Furthermore, we found Rho associated coiled-coil containing protein kinase 1 (ROCK1) cleavage/activation played a critical role in Lycorine-induced mitochondrial apoptosis. In addition, the ROCK inhibitor Y-27632 was employed, and we found that co-treatment with Y-27632 partly attenuated Lycorine-induced ROCK1 activation and mitochondrial apoptosis. Meanwhile, an in vivo study revealed that Lycorine inhibited tumour growth and induced apoptosis in a HepG2 xenograft mouse model in association with ROCK1 activation. Taken together, all these findings suggested that Lycorine induced mitochondria-dependent apoptosis through ROCK1 activation in HepG2 cells, and this may be a theoretical basis for Lycorine’s anticancer effects.
-
Lycorine inhibits cell proliferation and migration by inhibiting rock1 cofilin induced actin dynamics in hepg2 hepatoblastoma cells
Oncology Reports, 2018Co-Authors: Wuyi Liu, Qian Zhang, Qin Tang, Jingbin Huang, Yali Liu, Qing Wang, Rong ZhangAbstract:Lycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit anti‑cancer effects in various types of cancer cells. However, the molecular mechanisms through which Lycorine exhibits anti‑hepatoblastoma activity are unclear. In the present study, the inhibitory effects of Lycorine on the proliferation and migration of HepG2 hepatoblastoma cells were investigated. Lycorine inhibited the proliferation of HepG2 cells in a dose‑dependent manner by inducing cell cycle arrest at the G2/M phase, via downregulation of cyclin A, cyclin B1 and cyclin dependent kinase 1. Additionally, wound healing and Transwell assays revealed that treatment with Lycorine resulted in a decrease in the migratory ability of HepG2 cells. Also, treatment with Lycorine decreased the expression levels of matrix metalloproteinase (MMP)‑9 and MMP‑2. Furthermore, Lycorine induced the cleavage/activation of Rho associated coiled‑coil containing protein kinase 1 (ROCK1) and the downregulation of cofilin, accompanied by an increase in polymerized filamentous actin and a loss of depolymerized globular actin. Furthermore, pre‑incubation of cells with Y‑27632, a specific ROCK1 inhibitor, markedly attenuated Lycorine‑induced anti‑proliferative and anti‑migration effects. Taken together, the results demonstrated that Lycorine inhibited the proliferation and migration of HepG2 cells by suppressing ROCK1/cofilin‑induced actin dynamics, which suggests that Lycorine has the potential to be developed into a novel drug for hepatoblastoma treatment.
-
Lycorine inhibits cell proliferation and migration by inhibiting ROCK1/cofilin‑induced actin dynamics in HepG2 hepatoblastoma cells.
Oncology reports, 2018Co-Authors: Wuyi Liu, Qian Zhang, Qin Tang, Jingbin Huang, Yali Liu, Wang Qing, Rong ZhangAbstract:Lycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit anti‑cancer effects in various types of cancer cells. However, the molecular mechanisms through which Lycorine exhibits anti‑hepatoblastoma activity are unclear. In the present study, the inhibitory effects of Lycorine on the proliferation and migration of HepG2 hepatoblastoma cells were investigated. Lycorine inhibited the proliferation of HepG2 cells in a dose‑dependent manner by inducing cell cycle arrest at the G2/M phase, via downregulation of cyclin A, cyclin B1 and cyclin dependent kinase 1. Additionally, wound healing and Transwell assays revealed that treatment with Lycorine resulted in a decrease in the migratory ability of HepG2 cells. Also, treatment with Lycorine decreased the expression levels of matrix metalloproteinase (MMP)‑9 and MMP‑2. Furthermore, Lycorine induced the cleavage/activation of Rho associated coiled‑coil containing protein kinase 1 (ROCK1) and the downregulation of cofilin, accompanied by an increase in polymerized filamentous actin and a loss of depolymerized globular actin. Furthermore, pre‑incubation of cells with Y‑27632, a specific ROCK1 inhibitor, markedly attenuated Lycorine‑induced anti‑proliferative and anti‑migration effects. Taken together, the results demonstrated that Lycorine inhibited the proliferation and migration of HepG2 cells by suppressing ROCK1/cofilin‑induced actin dynamics, which suggests that Lycorine has the potential to be developed into a novel drug for hepatoblastoma treatment.
Chaoying Yang - One of the best experts on this subject based on the ideXlab platform.
-
Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
British journal of haematology, 2020Co-Authors: Haiqin Wang, Yanfei Gong, Mridul Roy, Liang Long, Ling Xiao, Jiliang Xia, Wen Zhou, Chaoying YangAbstract:Multiple myeloma (MM) is characterised by the proliferation and accumulation of malignant plasma cells in the bone marrow. Despite the progress in treatment over the last few years, MM remains incurable and the majority of patients relapse. MM stem-like cells (MMSCs) have been considered as the main reason for drug resistance and eventual relapse. Currently, therapeutic agents are not enough to eradicate MMSCs, and finding effective strategies to eradicate MMSCs may improve the outcome of patients. Here we showed that Lycorine, a natural compound from the Amaryllidaceae species, effectively inhibits the proliferation of myeloma cells from cell lines or patients, mainly through decreasing ALDH1+ cells. Mechanistically, Lycorine decreases the MMSC population through inhibition of the Wnt/β-catenin pathway by reducing the β-catenin protein level. Moreover, Lycorine could overcome the increasing proportion of ALDH1+ cells caused by bortezomib (BTZ) treatment, and a combination BTZ and Lycorine have a synergistic effect on anti-myeloma cells. Furthermore, we found a similar reduction of MMSC characteristics by Lycorine in BTZ-resistant MM cells and primary CD138+ plasma cells. Collectively, our findings indicate Lycorine as a promising agent to target MMSCs to overcome the drug resistance of BTZ, and that, alone or in combination with BTZ, Lycorine is a potential therapeutic strategy for MM treatments.
-
Lycorine targets multiple myeloma stem cell like cells by inhibition of wnt β catenin pathway
British Journal of Haematology, 2020Co-Authors: Haiqin Wang, Long Liang, Yanfei Gong, Mridul Roy, Ling Xiao, Jiliang Xia, Wen Zhou, Chaoying YangAbstract:Multiple myeloma (MM) is characterised by the proliferation and accumulation of malignant plasma cells in the bone marrow. Despite the progress in treatment over the last few years, MM remains incurable and the majority of patients relapse. MM stem-like cells (MMSCs) have been considered as the main reason for drug resistance and eventual relapse. Currently, therapeutic agents are not enough to eradicate MMSCs, and finding effective strategies to eradicate MMSCs may improve the outcome of patients. Here we showed that Lycorine, a natural compound from the Amaryllidaceae species, effectively inhibits the proliferation of myeloma cells from cell lines or patients, mainly through decreasing ALDH1+ cells. Mechanistically, Lycorine decreases the MMSC population through inhibition of the Wnt/β-catenin pathway by reducing the β-catenin protein level. Moreover, Lycorine could overcome the increasing proportion of ALDH1+ cells caused by bortezomib (BTZ) treatment, and a combination BTZ and Lycorine have a synergistic effect on anti-myeloma cells. Furthermore, we found a similar reduction of MMSC characteristics by Lycorine in BTZ-resistant MM cells and primary CD138+ plasma cells. Collectively, our findings indicate Lycorine as a promising agent to target MMSCs to overcome the drug resistance of BTZ, and that, alone or in combination with BTZ, Lycorine is a potential therapeutic strategy for MM treatments.
Mridul Roy - One of the best experts on this subject based on the ideXlab platform.
-
Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
British journal of haematology, 2020Co-Authors: Haiqin Wang, Yanfei Gong, Mridul Roy, Liang Long, Ling Xiao, Jiliang Xia, Wen Zhou, Chaoying YangAbstract:Multiple myeloma (MM) is characterised by the proliferation and accumulation of malignant plasma cells in the bone marrow. Despite the progress in treatment over the last few years, MM remains incurable and the majority of patients relapse. MM stem-like cells (MMSCs) have been considered as the main reason for drug resistance and eventual relapse. Currently, therapeutic agents are not enough to eradicate MMSCs, and finding effective strategies to eradicate MMSCs may improve the outcome of patients. Here we showed that Lycorine, a natural compound from the Amaryllidaceae species, effectively inhibits the proliferation of myeloma cells from cell lines or patients, mainly through decreasing ALDH1+ cells. Mechanistically, Lycorine decreases the MMSC population through inhibition of the Wnt/β-catenin pathway by reducing the β-catenin protein level. Moreover, Lycorine could overcome the increasing proportion of ALDH1+ cells caused by bortezomib (BTZ) treatment, and a combination BTZ and Lycorine have a synergistic effect on anti-myeloma cells. Furthermore, we found a similar reduction of MMSC characteristics by Lycorine in BTZ-resistant MM cells and primary CD138+ plasma cells. Collectively, our findings indicate Lycorine as a promising agent to target MMSCs to overcome the drug resistance of BTZ, and that, alone or in combination with BTZ, Lycorine is a potential therapeutic strategy for MM treatments.
-
Lycorine targets multiple myeloma stem cell like cells by inhibition of wnt β catenin pathway
British Journal of Haematology, 2020Co-Authors: Haiqin Wang, Long Liang, Yanfei Gong, Mridul Roy, Ling Xiao, Jiliang Xia, Wen Zhou, Chaoying YangAbstract:Multiple myeloma (MM) is characterised by the proliferation and accumulation of malignant plasma cells in the bone marrow. Despite the progress in treatment over the last few years, MM remains incurable and the majority of patients relapse. MM stem-like cells (MMSCs) have been considered as the main reason for drug resistance and eventual relapse. Currently, therapeutic agents are not enough to eradicate MMSCs, and finding effective strategies to eradicate MMSCs may improve the outcome of patients. Here we showed that Lycorine, a natural compound from the Amaryllidaceae species, effectively inhibits the proliferation of myeloma cells from cell lines or patients, mainly through decreasing ALDH1+ cells. Mechanistically, Lycorine decreases the MMSC population through inhibition of the Wnt/β-catenin pathway by reducing the β-catenin protein level. Moreover, Lycorine could overcome the increasing proportion of ALDH1+ cells caused by bortezomib (BTZ) treatment, and a combination BTZ and Lycorine have a synergistic effect on anti-myeloma cells. Furthermore, we found a similar reduction of MMSC characteristics by Lycorine in BTZ-resistant MM cells and primary CD138+ plasma cells. Collectively, our findings indicate Lycorine as a promising agent to target MMSCs to overcome the drug resistance of BTZ, and that, alone or in combination with BTZ, Lycorine is a potential therapeutic strategy for MM treatments.
-
Lycorine: A prospective natural lead for anticancer drug discovery.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018Co-Authors: Mridul Roy, Xiaojuan Xiao, Long Liang, Peifu Feng, Jing LiuAbstract:Nature is the most abundant source for novel drug discovery. Lycorine is a natural alkaloid with immense therapeutic potential. Lycorine is active in a very low concentration and with high specificity against a number of cancers both in vivo and in vitro and against various drug-resistant cancer cells. This review summarized the therapeutic effect and the anticancer mechanisms of Lycorine. At the same time, we have discussed the pharmacology and comparative structure-activity relationship for the anticancer activity of this compound. The researches outlined in this paper serve as a foundation to explain Lycorine as an important lead compound for new generation anticancer drug design and provide the principle for the development of biological strategies to utilize Lycorine in the treatment of cancers.
-
Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma
Blood, 2016Co-Authors: Mridul Roy, Xiaojuan Xiao, Long Liang, Yuhao Luo, Yuanliang Peng, Weihua Zhou, Ji Zhang, Lugui Qiu, Shuaishuai Zhang, Feng LiuAbstract:Multiple myeloma (MM) is the second most prevalent hematologic malignancy, characterized by the infiltration of malignant plasma cells into bone marrow. In spite of current efficient therapeutic regimens, which have significantly increased patients overall survival, the major features inevitably present in MM are the intrinsic and acquired resistance with nearly universal relapse. In addition, the diverse heterogeneous characteristics of this largely incurable disease emphasize the importance of innovative therapies and identification of more effective drugs. Autophagy removes defective cellular organelles, protein aggregates, and intracellular microbes and is associated with cell survival and tumor maintenance. Inhibition of autophagy enhances sensitivity of a number of anticancer agents and induces cell death in MM. High-mobility group box-1 (HMGB1) protein plays an important subcellular localization-dependent role during autophagy. The importance of HMGB1 for induction of autophagy and tumor development has made this protein as a novel target for cancer therapy. Lycorine is a natural alkaloid with significant anti-cancer activity. While previous studies mainly showed Lycorine as a potential apoptosis inducer, recent studies stated that apoptosis is not the primary underlying anti-proliferative mechanism of this compound. This led the interest to investigate the role of Lycorine on other cell maintenance systems, such as autophagy. In addition single-agent efficacy of Lycorine or in combination with other anti-MM agents has not been evaluated in vivo. Herein we investigated the anti-MM effect of Lycorine and the role of this natural agent on regulation of autophagy in vitro and in vivo. We found that Lycorine inhibits proliferation and induces apoptosis in MM cells with less sensitivity to the normal B-cell at the same concentrations. We also found that Lycorine promisingly inhibits autophagy, the mechanism that MM cells use to survive and defeat treatment. We identified HMGB1, an important regulator of autophagy, as the most aberrantly expressed protein after Lycorine treatment. Furthermore, we characterized HMGB1 as a critical mediator of Lycorine activity against MM. Gene expression profiling (GEP) analysis showed that higher expression of HMGB1 is linked with the poor prognosis of MM. We further confirmed this correlation in human bone marrow CD138 + primary myeloma cells and MM cell lines. Mechanistically, by activating the proteasomal degradation of HMGB1, Lycorine induces a rapid turnover of HMGB1. This led to decreased Bcl-2 phosphorylation by MEK-ERK pathway and increased association of Bcl-2 with Beclin-1 resulting in autophagy inhibition and growth attenuation. In addition, we observed higher HMGB1 expression in bortezomib resistant cells. The combination of bortezomib plus Lycorine was highly efficient against MM cells and MM cells grown in bone marrow micro-environment. Lycorine showed the capability of inhibiting bortezomib induced autophagy as well as re-sensitizing resistant cells to bortezomib. In agreement with our in vitro observations, in vivo study using human MM xenograft model showed that Lycorine is well tolerated, inhibits HMGB1 expression and thereby autophagy and induces enhanced bortezomib activity. These observations indicated Lycorine as an effective autophagy inhibitor and revealed that Lycorine alone or in combination with bortezomib is a potential therapeutic strategy. Our study supports the feasibility of Lycorine in anti-MM treatment and provides a preclinical framework for combining Lycorine with bortezomib in clinical setting. Disclosures No relevant conflicts of interest to declare.
-
Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma
Theranostics, 2016Co-Authors: Mridul Roy, Xiaojuan Xiao, Long Liang, Yuhao Luo, Yuanliang Peng, Weihua Zhou, Ji Zhang, Lugui Qiu, Shuaishuai Zhang, Feng LiuAbstract:Multiple myeloma (MM) is largely incurable and drug-resistant. Novel therapeutic approaches such as inhibiting autophagy or rational drug combinations are aimed to overcome this issue. In this study, we found that Lycorine exhibits a promising anti-proliferative activity against MM in vitro and in vivo by inhibiting autophagy. We identified High mobility group box 1 (HMGB1), an important regulator of autophagy, as the most aberrantly expressed protein after Lycorine treatment and as a critical mediator of Lycorine activity. Gene expression profiling (GEP) analysis showed that higher expression of HMGB1 is linked with the poor prognosis of MM. This correlation was further confirmed in human bone marrow CD138+ primary myeloma cells and MM cell lines. Mechanistically, proteasomal degradation of HMGB1 by Lycorine inhibits the activation of MEK-ERK thereby decreases phosphorylation of Bcl-2 resulting in constitutive association of Bcl-2 with Beclin-1. In addition, we observed higher HMGB1 expression in bortezomib resistant cells and the combination of bortezomib plus Lycorine was highly efficient in vitro and in vivo myeloma models as well as in re-sensitizing resistant cells to bortezomib. These observations indicate Lycorine as an effective autophagy inhibitor and reveal that Lycorine alone or in combination with bortezomib is a potential therapeutic strategy.
Meiying Ning - One of the best experts on this subject based on the ideXlab platform.
-
Lycorine inhibited the cell growth of non small cell lung cancer by modulating the mir 186 cdk1 axis
Life Sciences, 2019Co-Authors: Zao Zhang, Qian Yang, Meiying NingAbstract:Abstract Aims Lycorine is a kind of natural alkaloid with anti-cancer potential. It has been demonstrated that Lycorine processes high activity and specificity against the progression of cancers. However, the underlying molecular mechanisms by which Lycorine regulates the formation and development of non-small cell lung cancer (NSCLC) remain largely unknown. Main methods The effects of Lycorine on the growth of NSCLC cells were determined by the cell counting kit-8 (CCK-8) assay, colony formation and flow cytometry analysis. RT-qPCR was performed to detect the expression of microRNA with Lycorine treatment. The binding of miRNA and target genes was confirmed by luciferase reporter assay. Key findings Lycorine significantly inhibited the proliferation and induced apoptosis of NSCLC cells. Mechanistically, Lycorine up-regulated the expression of microRNA-186 in NSCLC cells. Depletion of miR-186 significantly reversed the suppressive effect of Lycorine on the proliferation of NSCLC cells. Furthermore, the cyclin dependent kinase 1 (CDK1) was identified as one of the binding candidates of miR-186. Experimental analysis showed that miR-186 bound the 3′-untranslated region (3′-UTR) of CDK1 and suppressed the level of CDK1 in NSCLC cells. Consistently, exposure of Lycorine significantly decreased the expression of CDK1. Restoration of CDK1 remarkably attenuated the inhibition of Lycorine on the proliferation of NSCLC cells. Significance Our results uncovered the novel molecular mechanism of Lycorine in suppressing the progression of NSCLC partially via regulating the miR-186/CDK1 axis.
-
Lycorine inhibited the cell growth of non-small cell lung cancer by modulating the miR-186/CDK1 axis.
Life sciences, 2019Co-Authors: Zao Zhang, Qian Yang, Meiying NingAbstract:Abstract Aims Lycorine is a kind of natural alkaloid with anti-cancer potential. It has been demonstrated that Lycorine processes high activity and specificity against the progression of cancers. However, the underlying molecular mechanisms by which Lycorine regulates the formation and development of non-small cell lung cancer (NSCLC) remain largely unknown. Main methods The effects of Lycorine on the growth of NSCLC cells were determined by the cell counting kit-8 (CCK-8) assay, colony formation and flow cytometry analysis. RT-qPCR was performed to detect the expression of microRNA with Lycorine treatment. The binding of miRNA and target genes was confirmed by luciferase reporter assay. Key findings Lycorine significantly inhibited the proliferation and induced apoptosis of NSCLC cells. Mechanistically, Lycorine up-regulated the expression of microRNA-186 in NSCLC cells. Depletion of miR-186 significantly reversed the suppressive effect of Lycorine on the proliferation of NSCLC cells. Furthermore, the cyclin dependent kinase 1 (CDK1) was identified as one of the binding candidates of miR-186. Experimental analysis showed that miR-186 bound the 3′-untranslated region (3′-UTR) of CDK1 and suppressed the level of CDK1 in NSCLC cells. Consistently, exposure of Lycorine significantly decreased the expression of CDK1. Restoration of CDK1 remarkably attenuated the inhibition of Lycorine on the proliferation of NSCLC cells. Significance Our results uncovered the novel molecular mechanism of Lycorine in suppressing the progression of NSCLC partially via regulating the miR-186/CDK1 axis.
